Author:
Zitouni Nesrine B.,Arnault Jean-Philippe,Dadban Ali,Attencourt Christophe,Lok Catherine C.,Chaby Guillaume
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Dermatology,Oncology
Reference18 articles.
1. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: role in advanced cancers;Rajan;Hum Vaccin Immunother,2016
2. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J Clin Oncol,2010
3. Varied immuno-related adverse events induced by immune-check point inhibitors – Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6;Okiyama;Nihon Rinsho Meneki Gakkai Kaishi,2017
4. Subacute cutaneous lupus erythematosus induced by nivolumab;Liu;Australas J Dermatol,2018
5. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab;Topalian;J Clin Oncol,2014
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献